Your browser is no longer supported. Please, upgrade your browser.
Settings
AUPH Aurinia Pharmaceuticals Inc. daily Stock Chart
AUPH [NASD]
Aurinia Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.15 Insider Own- Shs Outstand83.97M Perf Week5.86%
Market Cap470.25M Forward P/E- EPS next Y-0.55 Insider Trans- Shs Float46.35M Perf Month-6.04%
Income- PEG- EPS next Q-0.15 Inst Own- Short Float20.19% Perf Quarter9.59%
Sales0.42M P/S1122.31 EPS this Y-54.50% Inst Trans- Short Ratio9.90 Perf Half Y-7.59%
Book/sh2.00 P/B2.81 EPS next Y46.10% ROA- Target Price11.92 Perf Year70.73%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.23 - 10.54 Perf YTD23.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.87% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low73.37% ATR0.27
Employees12 Current Ratio- Sales Q/Q-6.50% Oper. Margin- RSI (14)60.98 Volatility4.30% 5.16%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.80 Prev Close5.46
ShortableYes LT Debt/Eq- EarningsMar 08 AMC Payout- Avg Volume945.86K Price5.60
Recom1.70 SMA205.93% SMA508.33% SMA200-5.71% Volume753,387 Change2.56%
Feb-08-18Initiated RBC Capital Mkts Outperform $9
Oct-30-17Reiterated H.C. Wainwright Buy $10 → $12
May-18-17Reiterated H.C. Wainwright Buy $12 → $10
Apr-11-17Initiated Cantor Fitzgerald Overweight $14
Mar-22-17Reiterated FBR & Co. Outperform $9 → $11
Dec-30-16Reiterated H.C. Wainwright Buy $10 → $8
Aug-17-16Reiterated H.C. Wainwright Buy $7 → $10
Jun-30-16Initiated H.C. Wainwright Buy $7
May-08-15Initiated MLV & Co Buy $9
Feb-22-18 04:07PM  Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors Business Wire
07:54AM  Could Aurinia Pharmaceuticals Be a Millionaire-Maker Stock? Motley Fool
Feb-20-18 04:01PM  Aurinia Named Company of the Year by LifeSciences BC Business Wire
Feb-14-18 08:00AM  Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program Business Wire
Feb-10-18 11:02AM  February Growth Stocks To Look Out For Simply Wall St.
Feb-08-18 08:00AM  Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors Business Wire
Feb-06-18 08:00AM  Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference Business Wire +6.39%
Jan-19-18 11:28AM  A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent InvestorPlace
Jan-05-18 02:12PM  Here's What Knocked Aurinia Pharmaceuticals Inc. Down 16.1% in December Motley Fool
08:10AM  Todays Research Reports on Trending Tickers: Aurinia Pharmaceuticals Inc. and INSYS Therapeutics, Inc. ACCESSWIRE
Jan-04-18 05:16PM  Aurinia Pharmaceuticals Inc (AUPH) Shares Dip on New Shelf Registration SmarterAnalyst +5.42%
04:37PM  Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus Business Wire
Jan-03-18 06:32AM  3 Stocks Wall Street Hasn't Heard of Yet Motley Fool
Dec-25-17 09:22AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-19-17 07:34AM  Is Aurinia Pharmaceuticals a Buy? Motley Fool
Dec-11-17 06:16PM  Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index SmarterAnalyst
04:02PM  Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index Business Wire
Nov-21-17 11:02AM  Growth Stocks Investors Love Simply Wall St.
Nov-17-17 08:53AM  Aurinia Has Canaccord Captivated with Voclosporin Prospects SmarterAnalyst
Nov-16-17 09:24AM  Where Will Aurinia Pharmaceuticals Be in 5 Years? Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia Pharmaceuticals ACCESSWIRE
05:14AM  Aurinia reports 3Q loss Associated Press
Nov-15-17 02:58PM  H.C. Wainwright Likes Aurinia Pharmaceuticals Opportunity at Hand in the Lupus Nephritis Market SmarterAnalyst -6.37%
Nov-14-17 04:00PM  Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights Business Wire
01:15PM  What Does Aurinia Pharmaceuticals Incs (TSX:AUP) Share Price Indicate? Simply Wall St.
09:10AM  Aurinia Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Nov-13-17 08:39AM  Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season? Zacks
Nov-06-17 04:05PM  Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017 Business Wire
Oct-23-17 08:31AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : October 23, 2017 Capital Cube
Oct-20-17 09:00AM  Aurinia Pharmaceuticals Inc (AUPH) Announces Clinical Development for New Indications SmarterAnalyst
08:00AM  Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry Eye Syndrome Business Wire
Oct-16-17 08:43AM  Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options Zacks
08:36AM  Aurinia Pharmaceuticals (AUPH) Looks Good: Stock Adds 7.8% in Session Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Inotek Pharmaceuticals and Aurinia Pharmaceuticals ACCESSWIRE
06:42AM  Can The Uptrend Continue for Aurinia Pharmaceuticals (AUPH)? Zacks
Oct-13-17 08:37PM  Should You Buy Aurinia Pharmaceuticals Inc (AUPH)? Simply Wall St. +7.75%
06:02AM  Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap Motley Fool
Oct-12-17 07:00AM  Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America Business Wire
Oct-02-17 11:15AM  Aurinia Pharmaceuticals, Inc. Value Analysis (NASDAQ:AUPH) : October 2, 2017 Capital Cube +7.02%
Sep-29-17 08:15AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : September 29, 2017 Capital Cube
Sep-27-17 08:38AM  Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors Motley Fool
Sep-19-17 04:01PM  Aurinia to Host R&D Day and Webcast on October 20th in New York, NY Business Wire
Sep-14-17 10:19AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : September 14, 2017 Capital Cube
Sep-11-17 06:51PM  Should You Be Holding Aurinia Pharmaceuticals Inc (AUPH) Right Now? Simply Wall St.
Sep-05-17 01:05PM  Aurinia to Webcast at Upcoming Investor Conferences Business Wire
Sep-02-17 11:43AM  3 Charts That Show Why Aurinia Pharmaceuticals Stock Could Go Higher Motley Fool
Sep-01-17 09:51AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : September 1, 2017 Capital Cube
Aug-31-17 07:23PM  Market Bulls Continue on Quest for Strength TheStreet.com +6.74%
01:51PM  Shark Bites: Market Bulls Are Hot on the Trail of Strength TheStreet.com
Aug-24-17 10:25AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-17-17 09:03AM  3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now Motley Fool
Aug-10-17 09:54PM  Aurinia reports 2Q loss Associated Press
04:30PM  Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights Business Wire
Jul-31-17 05:35PM  Aurinia Pharmaceuticals, Inc. Value Analysis (NASDAQ:AUPH) : July 31, 2017 Capital Cube
Jul-28-17 09:31AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUPH-US : July 28, 2017 Capital Cube
Jul-25-17 02:28PM  An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals Motley Fool
Jul-21-17 02:42PM  3 Been-There-Done-That Biotech CEOs Who Are Doing it Again Motley Fool
Jul-20-17 09:02PM  3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now? Motley Fool
Jul-18-17 08:10AM  Today's Research Reports on Stocks to Watch: Soligenix and Aurinia Pharmaceuticals Accesswire -8.99%
Jul-17-17 07:00PM  Cramer Remix: Why its still worth owning Procter & Gamble CNBC +10.86%
09:01AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : July 17, 2017 Capital Cube
07:00AM  3 Small Biotech Stocks Being Run by Proven Winners Motley Fool
Jul-14-17 08:00PM  Is Aurinia Pharmaceuticals' Management Its Best Asset? Motley Fool +5.16%
Jul-12-17 09:31PM  After Its Drop, Is Aurinia Pharmaceuticals Stock Now A Buy? Motley Fool
09:15PM  Aurinia Resolves Temporary Non-Compliance with Nasdaqs Audit Committee Composition Rule Business Wire
Jul-10-17 08:32AM  Options Traders Expect Huge Moves in Aurinia Pharmaceuticals (AUPH) Stock Zacks
Jun-22-17 04:30PM  Aurinia Announces Results of Annual General Meeting Business Wire
Jun-21-17 07:00AM  Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC Business Wire
Jun-20-17 08:53AM  Do Options Traders Know Something About Aurinia Pharmaceuticals (AUPH) Stock We Don't? Zacks +9.97%
Jun-17-17 08:01AM  New Data Suggests Aurinia Pharmaceuticals Is Onto Something Big Motley Fool
Jun-16-17 10:45AM  Aurinia Pharma Rises Following Updated Mid-Stage Results 24/7 Wall St.
07:58AM  Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017 Business Wire
Jun-05-17 11:27AM  Aurinia Presents Additional Data from Phase IIB AURA-LV Study, Demonstrating Stable Renal Function and Blood Pressure without Electrolyte Complications Through 48 Weeks Business Wire
Jun-02-17 09:37AM  Aurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-30-17 04:19PM  Aurinia to Participate in Late Breaking Oral Presentations at Two Upcoming Scientific Conferences Business Wire -5.82%
May-17-17 04:02PM  Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis Business Wire
May-16-17 08:00AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Bellerophon Therapeutics Accesswire
May-15-17 08:47AM  Aurinia reports 1Q loss Associated Press -5.73%
08:00AM  Aurinia Reports First Quarter 2017 Financial Results, Announces Initiation of Phase III Aurora Clinical Trial, and Provides Operational Highlights Business Wire
May-11-17 06:12PM  Aurinia Pharmaceuticals, Inc. Value Analysis (NASDAQ:AUPH) : May 11, 2017 Capital Cube
May-09-17 09:00AM  Is a Surprise Coming for Aurinia Pharmaceuticals (AUPH) This Earnings Season? Zacks
08:25AM  Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUPH-US : May 9, 2017 Capital Cube
08:00AM  Pharma Industry Veteran Dr. George Milne Joins Aurinias Board of Directors Business Wire
May-01-17 02:32PM  3 Best Biotech Stocks During Trump's First 100 Days Motley Fool +5.28%
Apr-26-17 01:03PM  Aurinia to Present at Bloom Burton & Co. Healthcare Conference Business Wire +5.44%
Apr-21-17 07:30AM  Today's Research Reports on Stocks to Watch: Aurinia Pharmaceuticals and Immune Pharmaceuticals Accesswire
Apr-20-17 05:00PM  Aurinia Releases Additional 48-Week Data from the AURA-LV Study During Late-Breaking Session at the National Kidney Foundation 2017 Spring Clinical Meetings Business Wire
Apr-19-17 11:10AM  This Trading-Range Action Is Not Offering Much TheStreet.com
08:32AM  Implied Volatility Surging for Aurinia Pharmaceuticals(AUPH) Stock Options Zacks
Apr-17-17 04:02PM  Aurinia Completes Licensing Deal with Merck Animal Health for Its Nanomicellar Formulation of Voclosporin for the Treatment of Canine Dry Eye Syndrome Business Wire
Apr-10-17 01:30PM  Aurinia to Host Investor Event and Webcast on April 20th in Orlando, FL Business Wire
Apr-07-17 05:41PM  Aurinia Pharmaceuticals Plans to Take a Big Step Forward Motley Fool +6.98%
01:35PM  Here's Why Aurinia Pharmaceuticals Rose as Much as 10.8% This Morning Motley Fool
10:55AM  Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial 24/7 Wall St.
10:23AM  Aurinia Plans Phase 3 Study for Lupus Drug Investopedia
Apr-06-17 05:12PM  Aurinia Announces Development Plans for Voclosporin in Europe and Japan Business Wire
Apr-05-17 09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector Investopedia
09:27AM  Q1 Roundup: Winners and Losers of Biotech Sector
Apr-04-17 09:15AM  BC Tech Fund to Invest in Lumira Capital IV, L.P. CNW Group
09:15AM  BC Tech Fund to Invest in Lumira Capital IV, L.P.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.